Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELOM-080
- Development stage
- Unknown
- Lead developer
- Pohl-Boskamp
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
PB432 is an investigational drug designation for GeloMyrtol® forte, a phytotherapeutic product developed by G. Pohl-Boskamp. Its active ingredient is ELOM-080, a standardized distillate of four rectified essential oils: eucalyptus, sweet orange, lemon, and myrtle. PB432 is designed to enhance mucociliary clearance (MCC) by increasing ciliary beat frequency and restoring the airway's self-cleaning capacity, which can be impaired by viral infections such as SARS-CoV-2. While GeloMyrtol forte is widely used for the treatment of acute and chronic bronchitis and sinusitis, PB432 was specifically evaluated in the COVARI and COVARI-2 clinical trials as an add-on therapy for COVID-19 patients with acute respiratory insufficiency. The Phase II COVARI trial was terminated early due to recruitment challenges.
- Brand names
- GeloMyrtol forteGeloMyrtol
- Other names
- Myrtol standardizeddistillate of four rectified essential oils
02
Targets
15-LOX (Lysyl Oxidase)
Beyond the preview
Go deeper on ELOM-080.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELOM-080.